Essa Pharma Stock Price, News & Analysis

ESSA Pharma Inc. (NASDAQ: EPIX) presented preclinical data for its first generation androgen receptor (AR) degrader, EPI-8207, at the 34th EORTC-NCI-AACR Annual Symposium in Barcelona. The data shows EPI-8207 effectively degrades AR, including splice variants and mutants associated with castration-resistant prostate cancer. This research highlights the potential of ANITAC in targeting AR signaling, a key driver in prostate cancer progression. The study indicates EPI-8207's high potency in inhibiting AR-dependent transcription, positioning ESSA for advancements in prostate cancer therapy.

ESSA Pharma Inc. (NASDAQ: EPIX) announced promising results from a Phase 1/2 trial of its lead candidate, EPI-7386, in combination with enzalutamide for treating metastatic castration-resistant prostate cancer. The study showed that the combination therapy was safe with no dose-limiting toxicities, and 5 out of 6 patients experienced significant prostate-specific antigen (PSA) reductions. The pharmacokinetics indicated minimal impacts on enzalutamide exposure. ESSA is currently enrolling a third dose escalation cohort to optimize the therapeutic dose.

ESSA Pharma Inc. (NASDAQ: EPIX) announced the appointment of Philip Kantoff, M.D., to its Board of Directors, enhancing its leadership in prostate cancer treatment. Dr. Kantoff, a notable oncologist with extensive experience in clinical development, aims to assist ESSA in advancing its pipeline targeting the androgen receptor's N-terminal domain. His previous roles include CEO of Convergent Therapeutics and Chairman at Memorial Sloan Kettering Cancer Center. This strategic addition is expected to bolster ESSA's research and development efforts in prostate cancer therapies.

ESSA Pharma Inc. (NASDAQ: EPIX) provides a corporate update and financial results for Q3 ended June 30, 2022. The company reported a net loss of $8.8 million ($0.20 loss per share), consistent with the previous year. R&D expenditures increased slightly to $6.4 million. ESSA's lead candidate, EPI-7386, advanced to the dose expansion phase of its clinical trial, showing safety and initial anti-tumor activity. Cash reserves stand at $174.6 million, sufficient to fund operations through 2024.

ESSA Pharma Inc. (EPIX) presented promising Phase 1a trial results for EPI-7386, a novel prostate cancer treatment, indicating the drug was well-tolerated and achieved significant efficacy in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Out of 36 participants, the drug showed initial anti-tumor effects with reduced tumor volumes and stable PSA levels. The company plans to initiate a Phase 1b expansion study in Q3 2022. Notably, EPI-7386 may be explored in combination with other therapies to enhance its efficacy against prostate cancer.

ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company dedicated to prostate cancer therapies, is set to present at the 2022 Jefferies Healthcare Conference in New York City on June 9, 2022, at 3:00 p.m. ET. David R. Parkinson, the President and CEO, along with CFO David S. Wood, will participate in one-on-one meetings during the event. The presentation will follow a fireside chat format and will be accessible via a webcast on the company's website. The archived webcast will be available for 90 days.

ESSA Pharma Inc. (NASDAQ: EPIX) announced its fiscal second-quarter results for the period ending March 31, 2022, reporting a net loss of $10.9 million or $0.25 per share, an improvement from a $13.0 million loss a year ago. The company continues dosing patients in a Phase 1a trial of EPI-7386, a novel androgen receptor inhibitor for metastatic castration-resistant prostate cancer (mCRPC). ESSA's cash reserves stand at $181.0 million, sufficient to fund operations through 2024. Clinical updates on EPI-7386 are anticipated in 2022.

ESSA Pharma Inc. (NASDAQ: EPIX) announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022, at 2:30 p.m. ET. The company's President and CEO, David R. Parkinson, will host one-on-one meetings along with COO Peter Virsik and CFO David S. Wood. The event will be held at the Metro Toronto Convention Centre, offering investors insights into the latest developments in the healthcare sector. A webcast of the presentation will be available on ESSA's website and archived for 90 days.

ESSA Pharma Inc. (NASDAQ: EPIX) has announced the presentation of preclinical data on its ANITAC™ degraders at the 2022 American Association for Cancer Research Annual Meeting. ANITAC degraders target the N-terminal domain of androgen receptors, showing potential to degrade both full length and mutant forms in castration-resistant prostate cancer (CRPC). The data indicates these degraders can inhibit AR-dependent transcription and effectively reduce the viability of AR-dependent prostate cancer cells. Further developments are anticipated this year.